Included in the formulation
АТХ:R.02.A.A.06 Cetylpyridinium chloride
R.02.A.D.01 Benzocaine
Pharmacodynamics:The drug is a combination of benzocaine and cetylpyridinium chloride for topical application in ENT practice and dentistry.
The drug has a local anesthetic and antimicrobial effect.
Benzocaine is a local anesthetic. Benzocaine reduces pain when swallowing, which occurs with infectious inflammatory processes of the oral cavity and throat.
Cetylpyridinium chloride has a broad antimicrobial, antifungal and virucidal spectrum of action.
Pharmacokinetics:Cetylpyridinium chloride belongs to the class of quaternary ammonium salts and is absorbed only by 10-20%. The not absorbed part is excreted through the gastrointestinal tract unchanged.
Benzocaine is a hydrophobic molecule that is poorly soluble in water, which determines its minimum absorption. Absorbed benzocaine hydrolyzed mainly plasma cholinesterase, a small part is metabolized in the liver. Metabolites are excreted by the kidneys.
Indications:Infectious and inflammatory diseases of the mouth and throat: pharyngitis, laryngitis, the initial stage of angina; inflammation of the gums and mucous membrane of the mouth (gingivitis, stomatitis).
X.J00-J06.J02 Acute pharyngitis
X.J00-J06.J03 Acute tonsillitis
X.J00-J06.J04 Acute laryngitis and tracheitis
X.J30-J39.J31 Chronic rhinitis, nasopharyngitis and pharyngitis
X.J30-J39.J35.0 Chronic tonsillitis
X.J30-J39.J37 Chronic laryngitis and laryngotracheitis
XI.K00-K14.K05 Gingivitis and periodontal disease
XI.K00-K14.K12 Stomatitis and related lesions
Contraindications:Children under 6 years; hereditary intolerance to fructose; hypersensitivity to the components of the drug.
Carefully:With caution should be used in diabetes mellitus, open wounds of the oral cavity (because cetylpyridinium chloride slows healing of wounds).
Pregnancy and lactation:Data on the use of the drug during pregnancy and during breastfeeding are limited, so pregnant and lactating women are not recommended to take the drug.
Dosing and Administration:Adults and children over the age of 12 years it is recommended to dissolve 1 lozenge every 2-3 hours, but not more than eight lozenges a day.
Children aged 6 to 12 years it is recommended to dissolve 1 lozenge every 4 hours, but not more than four lozenges a day.
The drug should not be taken immediately before meals and at the same time as milk.
Side effects:From the digestive system: very rarely - nausea, diarrhea, when the manifestation of which the drug should be stopped.
The preparation contains polyols (maltitol, mannitol), which in high doses can cause diarrhea, especially in children.
Other: very rarely - allergic reactions.
Overdose:Given the number of active substances contained in 1 lozenge, the possibility of an overdose is minimal.
Symptoms: When exceeding the recommended dosage, there may be abnormalities in the gastrointestinal tract (nausea, vomiting and diarrhea). Benzocaine in high doses can cause methemoglobinemia, and cetylpyridinium chloride - vomiting and nausea.
Treatment: the patient should stop taking the drug and consult a doctor.
Interaction:The cases of drug interaction with other drugs have not been described.
Simultaneous reception of the drug with food and milk reduces local antiseptic and anesthetic effects of the drug.
Special instructions:Do not exceed the recommended dose of the drug.
Patients with diabetes should be notified that 1 lozenge contains approximately 1 g of maltitol, for the metabolism of which insulin is needed. Due to slow hydrolysis and poor absorption from the gastrointestinal tract, maltitol affects the concentration of glucose in the plasma insignificantly. Therefore, correction of the dose of hypoglycemic drugs is not required. The energy value of maltitol (10 kJ / g or 2.4 kcal / g) is significantly lower than that of sucrose.
With more severe infectious processes accompanied by fever, headache and vomiting, it is necessary to see a doctor, especially if the condition does not improve within 3 days of the start of therapy.
The drug as a filler in its composition contains maltitol, so the drug should not be taken to patients with rare hereditary diseases associated with intolerance to fructose.
Impact on the ability to drive vehicles and manage mechanisms
There is no evidence that the drug affects the ability to drive and complex machinery.